| Ytd | -25.40% | |
| 1y | -58.51% |
| Open | 22.93 | Prev Close | 22.58 | Low | 22.89 | High | 24.20 | Mkt Cap | 1.34B |
| Vol | 1.31M | Avg Vol | 1.55M | EPS | -1.83 | P/E | N/A | Forward P/E | -25.95 |
| Beta | 0.85 | Short Ratio | 5.45 | Inst. Own | 102.39% | Dividend | N/A | Div Yield | N/A |
| Ex Div Date | N/A | Earning | 04-29 | 50-d Avg | 25.18 | 200-d Avg | 29.34 | 1yr Est | 30.20 |
PRCT News
Wall Street analysts upgraded various top stocks, including Nucor, Varonis, Invitation Homes, and Ma
Wall Street analysts changed outlook on top names, see all changes on Benzinga's analyst ratings
Evercore ISI Group analyst Vijay Kumar initiates coverage on PROCEPT BioRobotics (NASDAQ:PRCT) wi
Health care sector's oversold stocks present buying opportunity; RSI below 30 signals oversold,
Wall Street analysts changed outlook on top names like MKTX, PRCT, VOD, and JILL. See ratings page a
Leerink Partners analyst Mike Kratky downgrades PROCEPT BioRobotics (NASDAQ:PRCT) from Outperform
PROCEPT BioRobotics (NASDAQ:PRCT) today announced two milestones in its WATER IV prostate cancer cli
Piper Sandler analyst Matt O'Brien reiterates PROCEPT BioRobotics (NASDAQ:PRCT) with a Overwe
PROCEPT BioRobotics (NASDAQ:PRCT) affirms FY2026 sales outlook from $390.000 million-$410.000 millio
PROCEPT BioRobotics (NASDAQ:PRCT) reported quarterly losses of $(0.56) per share which met the analy
Baird analyst David Rescott initiates coverage on PROCEPT BioRobotics (NASDAQ:PRCT) with a Neutra
Truist Securities analyst Richard Newitter maintains PROCEPT BioRobotics (NASDAQ:PRCT) with a Buy
Leerink Partners analyst Mike Kratky maintains PROCEPT BioRobotics (NASDAQ:PRCT) with a Outperfor
TD Cowen analyst Joshua Jennings maintains PROCEPT BioRobotics (NASDAQ:PRCT) with a Buy and lower
Piper Sandler analyst Matt O'Brien maintains PROCEPT BioRobotics (NASDAQ:PRCT) with a Overwei
Wells Fargo analyst Nathan Treybeck maintains PROCEPT BioRobotics (NASDAQ:PRCT) with a Overweight
PROCEPT BioRobotics (NASDAQ: PRCT) shares down on Q4 2025 results and updated revenue guidance. Q1 s
PROCEPT BioRobotics (NASDAQ:PRCT) sees Q1 sales of $79.000 million-$82.000 million vs $92.646 millio
PROCEPT BioRobotics (NASDAQ:PRCT) reported quarterly losses of $(0.53) per share which missed the an
PROCEPT BioRobotics (NASDAQ:PRCT) lowers FY2026 sales outlook from $410.000 million-$430.000 million
Truist Securities analyst Richard Newitter maintains PROCEPT BioRobotics (NASDAQ:PRCT) with a Buy
UBS analyst Danielle Antalffy initiates coverage on PROCEPT BioRobotics (NASDAQ:PRCT) with a Buy
B of A Securities analyst Craig Bijou downgrades PROCEPT BioRobotics (NASDAQ:PRCT) from Buy to Ne
Morgan Stanley analyst Patrick Wood maintains PROCEPT BioRobotics (NASDAQ:PRCT) with a Overweight
TD Cowen analyst Joshua Jennings maintains PROCEPT BioRobotics (NASDAQ:PRCT) with a Buy and lower
Piper Sandler analyst Matt O'Brien reiterates PROCEPT BioRobotics (NASDAQ:PRCT) with a Overwe
Wells Fargo analyst Nathan Treybeck maintains PROCEPT BioRobotics (NASDAQ:PRCT) with a Overweight
PROCEPT BioRobotics (NASDAQ:PRCT) sees FY2026 sales of $410.000 million-$430.000 million vs $427.376
PROCEPT BioRobotics (NASDAQ:PRCT) affirms FY2025 sales outlook from $325.500 million to $325.500 mil
PROCEPT BioRobotics (NASDAQ:PRCT) reported quarterly losses of $(0.38) per share which beat the anal
Truist Securities analyst Richard Newitter maintains PROCEPT BioRobotics (NASDAQ:PRCT) with a Buy
Oppenheimer analyst Suraj Kalia upgrades PROCEPT BioRobotics (NASDAQ:PRCT) from Perform to Outper
Wells Fargo analyst Nathan Treybeck maintains PROCEPT BioRobotics (NASDAQ:PRCT) with a Overweight
Piper Sandler analyst Matt O'Brien maintains PROCEPT BioRobotics (NASDAQ:PRCT) with a Overwei